Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 4 Next >
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
From AIM ImmunoTech Inc.
Via GlobeNewswire
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Refutes Activist Group’s False and Misleading Claims
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Announces Cash Conservation Plan
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
From AIM ImmunoTech Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.